Burgess Michael F. 4
4 · SpringWorks Therapeutics, Inc. · Filed Jun 1, 2021
Insider Transaction Report
Form 4
Burgess Michael F.
Head of Research & Development
Transactions
- Award
Stock Option (Right to Buy)
2021-06-01+225,000→ 225,000 totalExercise: $81.68Exp: 2031-06-01→ Common Stock (225,000 underlying) - Award
Common Stock
2021-06-01+27,500→ 27,500 total
Footnotes (2)
- [F1]Represents restricted stock awards. The restricted stock awards shall vest as follows: thirty three percent (33%) to vest on June 1, 2022, another thirty three percent (33%) to vest on June 1, 2023 and the remaining thirty four percent (34%) to vest on June 1, 2024, such that the restricted stock awards are fully vested on June 1, 2024, subject to continued service to the Company by the Reporting Person.
- [F2]This option shall vest as follows: twenty five percent (25%) on June 1, 2022, and thereafter in thirty six (36) equal monthly installments until fully vested, subject to continued service to the Company by the Reporting Person.